We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
(+2.7%)
Cap. Flow
-$803K
Cap. Flow
% of AUM
-0.33%
Top 10 Holdings %
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$673K |
| 2 |
Zai Lab
ZLAB
|
+$472K |
| 3 |
Stellus Capital Investment Corp
SCM
|
+$422K |
| 4 |
DRD
DRDGold
DRD
|
+$415K |
| 5 |
OXLC
Oxford Lane Capital
OXLC
|
+$359K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRS
Amyris Inc.
AMRS
|
+$1.16M |
| 2 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$664K |
| 3 |
BioNTech
BNTX
|
+$663K |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$645K |
| 5 |
Prothena Corp
PRTA
|
+$590K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.38% |
| 2 | Real Estate | 18.81% |
| 3 | Energy | 13.29% |
| 4 | Materials | 10.7% |
| 5 | Utilities | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Gossamer Bio
GOSS
$72.2M
| $206K | 0.08% |
25,361
-3,102
| -11% | -$26.9K |
|
|
KRON
327
DELISTED
Kronos Bio
KRON
| $205K | 0.08% |
+8,554
| New | +$217K |
|
328
Passage Bio
PASG
$15.6M
| $205K | 0.08% |
+773
| New | +$239K |
|
329
Revolution Medicines
RVMD
$40.2B
| $205K | 0.08% |
6,471
-454
| -7% | -$15.8K |
|
330
Arvinas
ARVN
$534M
| $204K | 0.08% |
2,655
-2,496
| -48% | -$173K |
|
331
Wave Life Sciences
WVE
$1.14B
| $204K | 0.08% |
30,600
-2,003
| -6% | -$13.1K |
|
332
Zymeworks
ZYME
$1.71B
| $204K | 0.08% |
5,894
+56
| +1% | +$1.78K |
|
333
ALX Oncology
ALXO
$276M
| $203K | 0.08% |
3,718
-40
| -1% | -$2.39K |
|
334
Cytokinetics
CYTK
$10.9B
| $203K | 0.08% |
10,237
-3,899
| -28% | -$91.5K |
|
|
MRSN
335
DELISTED
Mersana Therapeutics
MRSN
| $203K | 0.08% |
596
+125
| +27% | +$47.3K |
|
336
Syndax Pharmaceuticals
SNDX
$1.85B
| $203K | 0.08% |
11,835
+7
| +0.1% | +$128 |
|
|
TCRR
337
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $203K | 0.08% |
12,379
+1,696
| +16% | +$34.3K |
|
338
Atea Pharmaceuticals
AVIR
$386M
| $202K | 0.08% |
+9,395
| New | +$282K |
|
339
Madrigal Pharmaceuticals
MDGL
$12.9B
| $202K | 0.08% |
2,078
-402
| -16% | -$47.6K |
|
340
Scholar Rock
SRRK
$5.91B
| $202K | 0.08% |
6,975
+718
| +11% | +$22K |
|
341
C4 Therapeutics
CCCC
$394M
| $201K | 0.08% |
+5,312
| New | +$190K |
|
342
Nurix Therapeutics
NRIX
$2.45B
| $201K | 0.08% |
+7,570
| New | +$222K |
|
343
Oric Pharmaceuticals
ORIC
$1.25B
| $201K | 0.08% |
11,349
+2,955
| +35% | +$64.8K |
|
|
HARP
344
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $201K | 0.08% |
1,449
-676
| -32% | -$129K |
|
|
ATNX
345
DELISTED
Athenex, Inc. Common Stock
ATNX
| $201K | 0.08% |
2,180
+958
| +78% | +$87.1K |
|
346
AbCellera Biologics
ABCL
$1.64B
| $200K | 0.08% |
+9,111
| New | +$251K |
|
347
Kura Oncology
KURA
$936M
| $200K | 0.08% |
9,572
+2,304
| +32% | +$57.2K |
|
348
Alaunos Therapeutics
TCRT
$4.71M
| $200K | 0.08% |
506
-142
| -22% | -$66.3K |
|
|
GRTS
349
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $200K | 0.08% |
+21,930
| New | +$203K |
|
|
GRCL
350
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $200K | 0.08% |
+15,363
| New | +$206K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.
Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.
- Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
- Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
- Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
- Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
- Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
- Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
- Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.